NCT04305444 2025-01-08
Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas
Zhejiang DTRM Biopharma
Phase 2 Terminated
Clinical Trials
12 trialsNCT01678664 2024-09-25
EVACEL
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT00811590 2024-09-19
Pilot Study of mTOR Inhibitor Therapy in Peutz-Jeghers Syndrome
University of Utah
Phase 2 Terminated
NCT03239015 2022-03-04
Efficacy and Safety of Precision Therapy in Refractory Tumor
Shanghai Changzheng Hospital
Phase 2 Unknown
NCT02315625 2020-09-09
Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT02017860 2020-04-30
Study to Collect and Assess Long-term Safety of Everolimus in Patients Who Are on Everolimus Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator.
Novartis
Phase 2 Completed
NCT01376310 2019-02-19
GSK1120212 Rollover Study
Novartis
Phase 2 Terminated
NCT00529802 2018-04-25
Exploratory Study Evaluating Fluorodeoxyglucose - Position Emission Tomography as a Predictive Marker for Therapy With RAD001 in Metastatic Renal Cell Cancer
University of Chicago
Phase 2 Completed
NCT01031381 2016-08-30
RADBEV
University of Pittsburgh
Phase 2 Completed
NCT01178151 2015-04-22
EVAMP
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 2 Withdrawn
NCT01127763 2014-04-09
RAD001 Plus Carboplatin in Breast Cancer Patients
NYU Langone Health
Phase 2 Completed
NCT00363051 2013-05-10
Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy
Novartis
Phase 2 Completed